10-Q quarterly report · filed Nov 4, 2026

Insulet Corporation (PODD) Q3 2026 10-Q Quarterly Report

Short answer

Insulet Corporation (PODD) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $842M (up 19.2% year over year) with net income of $141M.

Q3 2026 key financials · XBRL

Revenue
$842M
+19.2% YoY · +5.0% QoQ
Net income
$141M
+61.0% YoY · +48.4% QoQ
Operating margin
22.5%
Gross margin
75.1%
EPS (diluted)
$2.02
+64.2% YoY · +47.4% QoQ

Source: XBRL data from the Insulet Corporation (PODD) Q3 2026 10-Q on SEC EDGAR. USD.

Insulet Corporation Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $842.0M, up 19.2% YoY from $706.3M, driven by Omnipod Products growth
  • Gross margin 75.1% vs 72.2% YoY, benefiting from manufacturing efficiencies and warranty accrual adjustment
  • International Omnipod revenue $266.2M, up 31.7%; Drug Delivery $5.5M, down 22.7%
  • Operating cash flow $325.7M, down from $386.0M; capital expenditures $113.9M and share repurchases $300.0M
  • 2026 capital expenditures expected to increase; tariff exemption removal could materially pressure future gross margin

Risk Factors

  • No material changes to risks disclosed in the December 31, 2025 Form 10-K
  • Carried-forward risks include business, financial condition, results of operations, and cash flows exposures

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Insulet Corporation quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.